Marksans Pharma Limited
MARKSANS.NS- 1D
- +1.7%
Marksans Pharma Limited in brief
Marksans Pharma Limited is a listed company in the Pharmaceutical industry, based in India. Its market value was $1.5 B on 19 November 2026, which makes it the 7,648th largest listed company in the world and the 510th largest in India on this site. Its shares trade under the symbol MARKSANS.NS (NSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Marksans Pharma Limited timeline
- 2002
- 📈Listed on National Stock Exchange of India as MARKSANSFirst day of listing in the exchange's official list.
Events of Marksans Pharma Limited from the exchanges' official lists. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Marksans Pharma Limited share price · NSE (MARKSANS.NS)
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| Nov 19, 2026 | 295.50 | 299.90 | 290.55 | 299.05 | +1.5% | 704,579 |
| Nov 18, 2026 | 306.20 | 315.55 | 291.30 | 294.50 | -3.8% | 1.4 M |
| Nov 17, 2026 | 307.90 | 309.20 | 302.00 | 306.10 | -1.0% | 899,994 |
| Nov 16, 2026 | 318.50 | 318.90 | 307.65 | 309.20 | -2.9% | 1.2 M |
| Nov 13, 2026 | 323.70 | 328.70 | 315.50 | 318.50 | -0.5% | 1.7 M |
| Nov 12, 2026 | 306.00 | 322.95 | 305.85 | 320.00 | +4.4% | 2.1 M |
| Nov 11, 2026 | 310.00 | 310.45 | 303.05 | 306.55 | -0.7% | 1.2 M |
| Nov 9, 2026 | 305.60 | 313.50 | 305.20 | 308.75 | +1.7% | 823,630 |
| Nov 6, 2026 | 312.50 | 313.00 | 301.85 | 303.70 | -3.2% | 1.3 M |
| Nov 5, 2026 | 307.00 | 316.25 | 300.35 | 313.75 | +4.0% | 2.1 M |
| Nov 4, 2026 | 316.90 | 327.00 | 296.60 | 301.65 | -4.3% | 6.0 M |
| Nov 3, 2026 | 315.50 | 317.95 | 312.00 | 315.30 | +1.0% | 787,329 |
| Nov 2, 2026 | 306.90 | 314.50 | 305.90 | 312.30 | +2.0% | 835,052 |
| Oct 30, 2026 | 317.00 | 317.35 | 304.90 | 306.20 | -2.9% | 1.2 M |
| Oct 29, 2026 | 305.90 | 318.80 | 300.00 | 315.35 | +3.3% | 2.0 M |
| Oct 28, 2026 | 301.10 | 308.25 | 298.65 | 305.20 | +1.7% | 1.4 M |
| Oct 27, 2026 | 297.60 | 303.10 | 294.80 | 300.10 | +1.2% | 1.0 M |
| Oct 26, 2026 | 286.90 | 298.75 | 285.10 | 296.65 | +3.4% | 1.2 M |
| Oct 23, 2026 | 292.00 | 295.35 | 282.70 | 286.90 | -2.6% | 1.4 M |
| Oct 22, 2026 | 294.00 | 298.00 | 291.25 | 294.45 | -1.2% | 817,786 |
| Oct 21, 2026 | 304.65 | 306.75 | 293.60 | 298.15 | -1.6% | 1.4 M |
| Oct 19, 2026 | 311.00 | 314.50 | 302.00 | 303.05 | -2.6% | 817,392 |
| Oct 16, 2026 | 308.10 | 313.50 | 306.00 | 311.00 | +1.0% | 767,998 |
| Oct 15, 2026 | 314.20 | 315.10 | 306.55 | 307.85 | -2.0% | 681,887 |
| Oct 14, 2026 | 315.00 | 320.90 | 312.35 | 314.15 | -1.0% | 592,331 |
| Oct 13, 2026 | 316.95 | 318.00 | 309.80 | 317.25 | +0.3% | 1.0 M |
| Oct 12, 2026 | 310.00 | 318.00 | 309.00 | 316.40 | +2.4% | 822,584 |
| Oct 9, 2026 | 308.50 | 316.40 | 308.00 | 309.10 | +0.4% | 1.1 M |
| Oct 8, 2026 | 326.10 | 326.25 | 304.45 | 307.80 | -5.4% | 2.3 M |
| Oct 7, 2026 | 325.80 | 329.00 | 318.45 | 325.45 | — | 2.2 M |
Prices in INR from the National Stock Exchange of India; the last 30 trading days are listed, the chart shows up to ten years. For information only; not investment advice.
Marksans Pharma Limited share price statistics
Changes compare closing prices; volatility is the annualised standard deviation of daily returns. Prices are as published by the exchange, not adjusted for splits, bonus issues or dividends. For information only; not investment advice.
Market cap history
World rank over time
Rank in India: #739 (Jan 2020) · #487 (Jan 2021) · #721 (Jan 2022) · #683 (Dec 2022) · #557 (Jul 2023) · #520 (Jan 2024) · #491 (Mar 2026) · #631 (Aug 2026) · #481 (Nov 2026) · #488 (Nov 2026) · #491 (Nov 2026) · #498 (Nov 2026) · #509 (Nov 2026) · #510 (Nov 2026)
Mutual funds holding Marksans Pharma Limited#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 State Street SPDR Portfolio Emerging Markets ETFSSGA Funds Management, Inc. | 3.34 M | $10 M | 1.6% | 0.06% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Total International Stock Index FundThe Vanguard Group, Inc. | 3.14 M | $9 M | 1.5% | <0.01% | +10% | Jul 31, 2026 |
| 🇺🇸 Vanguard Emerging Markets Stock Index FundThe Vanguard Group, Inc. | 3.05 M | $8 M | 1.4% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Core MSCI Emerging Markets ETFBlackRock Fund Advisors | 2.09 M | $5 M | 0.98% | <0.01% | +4.5% | May 31, 2026 |
| 🇺🇸 Emerging Markets Core Equity 2 PortfolioDimensional Fund Advisors LP | 1.89 M | $5 M | 0.89% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets Value FundDimensional Fund Advisors LP | 930,270 | $3 M | 0.44% | 0.02% | −3.7% | Jul 31, 2026 |
| 🇺🇸 Vanguard Ftse All-World Ex-Us Small-Cap Index FundThe Vanguard Group, Inc. | 844,707 | $2 M | 0.40% | 0.02% | no change | Jul 31, 2026 |
| 🇮🇳 Motilal Oswal Nifty Microcap 250 Index FundMotilal Oswal Asset Management | 571,295 | $2 M | 0.27% | 0.81% | −1.9% | Oct 31, 2026 |
| 🇺🇸 The Emerging Markets Small Cap SeriesDimensional Fund Advisors LP | 631,683 | $2 M | 0.30% | 0.05% | no change | Jul 31, 2026 |
| 🇺🇸 WisdomTree India Earnings FundWisdomTree Asset Management, Inc. | 390,869 | $1 M | 0.18% | 0.05% | −5.6% | Jun 30, 2026 |
| 🇺🇸 iShares MSCI India Small-Cap ETFBlackRock Fund Advisors | 407,841 | $1 M | 0.19% | 0.17% | −5.4% | May 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets Core Equity 2 ETFDimensional Fund Advisors LP | 350,853 | $1 M | 0.17% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional Emerging Core Equity Market ETFDimensional Fund Advisors LP | 214,370 | $1 M | 0.10% | <0.01% | +33% | Jul 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 175,586 | $1 M | 0.08% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis Emerging Markets Equity ETFAmerican Century ETF Trust | 183,558 | $0 M | 0.09% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total International Index FundFidelity Management & Research Company LLC | 171,251 | $0 M | 0.08% | <0.01% | −1.3% | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S&P Emerging Markets Small Cap ETFSSGA Funds Management, Inc. | 147,382 | $0 M | 0.07% | 0.06% | −8.3% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total World Stock Index FundThe Vanguard Group, Inc. | 154,065 | $0 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S&P Emerging Asia Pacific ETFSSGA Funds Management, Inc. | 131,763 | $0 M | 0.06% | 0.09% | +7.7% | Jun 30, 2026 |
| 🇺🇸 Dimensional World ex. U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 122,626 | $0 M | 0.06% | <0.01% | +4.6% | Jul 31, 2026 |
| 🇺🇸 Avantis Emerging Markets Value ETFAmerican Century ETF Trust | 83,831 | $0 M | 0.04% | 0.01% | no change | May 31, 2026 |
| 🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP | 74,161 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Emerging Markets Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 60,249 | $0 M | 0.03% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 World ex U.S. Targeted Value PortfolioDimensional Fund Advisors LP | 59,055 | $0 M | 0.03% | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 Emerging Markets ex China Core Equity PortfolioDimensional Fund Advisors LP | 58,282 | $0 M | 0.03% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Emerging Markets Targeted Value PortfolioDimensional Fund Advisors LP | 51,545 | $0 M | 0.02% | 0.04% | no change | Jul 31, 2026 |
| 🇺🇸 State Street Global All Cap Equity ex-U.S. Index PortfolioSSGA Funds Management, Inc. | 38,479 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis Emerging Markets Equity FundAmerican Century ETF Trust | 42,291 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Esg International Stock ETFThe Vanguard Group, Inc. | 36,440 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets Value ETFDimensional Fund Advisors LP | 33,891 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets Sustainability Core 1 ETFDimensional Fund Advisors LP | 18,048 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional Emerging Markets ex China Core Equity ETFDimensional Fund Advisors LP | 11,710 | $0 M | <0.01% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional World ex U.S. Sustainability Targeted Value PortfolioDimensional Fund Advisors LP | 11,177 | $0 M | <0.01% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Avantis Emerging Markets Small Cap Equity ETFAmerican Century ETF Trust | 11,289 | $0 M | <0.01% | 0.02% | no change | May 31, 2026 |
| 🇺🇸 Avantis Emerging Markets ex-China Equity ETFAmerican Century ETF Trust | 3,171 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Oct 31, 2026. The 35 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Where Marksans Pharma Limited operates: 1 country#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
Only the headquarters country is on file for Marksans Pharma Limited: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.
| Country | Presence | Revenue there |
|---|---|---|
| 🇮🇳 India | Headquarters | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Product recalls by Marksans Pharma Limited#
3 recalls since 2015, 23,164,769 units in the notices that give a number. Drugs (FDA): 3.
| Date | What and why | Units | Notice |
|---|---|---|---|
| Time-Cap Labs, Inc. Metformin Hydrochloride Extended-Release Tablets USP 500 mg, a) 90 count (NDC 49483-623-09) b) 100 count (49483-623-01) c) 500 count (NDC 49483-623-50) and d) 1000 count (NDC 49483-623-10) bottles, Rx Only Manufactured for: Time-Cap Labs, Inc. 7 Michael Avenue Farmingdale, NY 11735, USA, Manufactured by: Mar… (and 1 more products)CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelDrugsClass II | 64,590 | D-0061-2021 | |
| Time-Cap Labs, Inc. Metformin Hydrochloride Extended-Release Tablets, USP 500 mg Rx Only 100 Tablets bottles, Manufactured for: Time-Cap Labs, Inc. 7 Michael Avenue Farmingdale, NY 11735, USA Manufactured by: Marksans Pharma Ltd. Plot No, L-82, L-83, Verna Intl. Estate, Verna, Goa-403 722, India NDC 49483-623-01CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelDrugsClass II | 11,279 | D-1356-2020 | |
| Ibuprofen Tablets, USP 600 mg, 6 x 2500 Tablets bulk packed in double polybag shipper packs for further packaging, Rx only, Manufactured by: Marksans Pharma Ltd., Plot No. L-82, L-83, Verna Indl. Estate, Verna, Goa - 403 722, India, NDC 25000-122-28. (and 5 more products)CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.DrugsClass II | 23,088,900 | D-0239-2018 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
Discuss Marksans Pharma Limited#
1 automatic updates and 0 member comments. Sign in to comment and react.
- Mutual funds: 35 funds hold $54 millionautomatic update · Oct 31, 2026
35 mutual funds in 2 countries hold shares of Marksans Pharma Limited worth $54 million, about 9.2% of the company (funds' newest reports, up to 31 October 2026). Since their previous reports 5 funds added shares and 6 sold; on balance they bought $920,000. Share splits are not counted as trading.
How Marksans Pharma Limited compares in Pharmaceutical
- Market cap$1.5 B · higher than 62% of 393
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Marksans Pharma Limited🇮🇳 | $1.5 B | — | — | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Nov 19, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, value.today research.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Marksans Pharma Limited? Verify and update this profile — free
Show Marksans Pharma Limited's ranking on your website Get the badge
The badge updates itself as the ranking changes.